M. B. Tedesco

发表

Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes.

W. Gooding, J. Gerich, Abraham Thomas, 2002, Diabetes care.

Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.

S. Sereika, A. F. Stewart, B. Hollis, 2010, The Journal of clinical endocrinology and metabolism.

Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.

A. F. Stewart, A. García-Ocaña, C. Gundberg, 2003, The Journal of clinical endocrinology and metabolism.

Evaluation of markers of bone turnover during lactation in African-Americans: a comparison with Caucasian lactation.

S. Sereika, A. F. Stewart, C. Gundberg, 2013, Journal of Clinical Endocrinology and Metabolism.

Continuous PTH and PTHrP Infusion Causes Suppression of Bone Formation and Discordant Effects on 1,25(OH)2Vitamin D

S. Sereika, A. F. Stewart, J. Wysolmerski, 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Safety and tolerability of subcutaneous PTHrP(1–36) in healthy human volunteers: a dose escalation study

S. Sereika, A. F. Stewart, B. Hollis, 2006, Osteoporosis International.

Retrospective analysis of HEART Score results in cost saving.

G. Hickey, M. B. Tedesco, C. Grant, 2019, Journal of the American Association of Nurse Practitioners.

Parathyroid hormone-related protein-(1--36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy.

S. Wisniewski, A. F. Stewart, A. García-Ocaña, 2001, The Journal of clinical endocrinology and metabolism.

Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers.

S. Sereika, A. F. Stewart, B. Hollis, 2003, The Journal of clinical endocrinology and metabolism.

A 7‐day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover

S. Sereika, A. F. Stewart, B. Hollis, 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Glucodynamics and pharmacokinetics of 70/30 vs. 50/50 NPH/regular insulin mixtures after subcutaneous injection.

M. Korytkowski, M. B. Tedesco, E. Krug, 2001, Diabetes care.

Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover.

S. Sereika, A. F. Stewart, B. Hollis, 2010, The Journal of clinical endocrinology and metabolism.

MENSTRUAL AND REPRODUCTIVE FUNCTION IN WOMEN WITH TYPE 1 DIABETES.

Magdalene Szuszkiewicz-Garcia, M. Korytkowski, S. Winters, 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

A comparison of parathyroid hormone‐related protein (1‐36) and parathyroid hormone (1‐34) on markers of bone turnover and bone density in postmenopausal women: The PrOP study

J. Cauley, S. Sereika, A. F. Stewart, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A Comparison of Parathyroid Hormone‐Related Protein (1–36) and Parathyroid Hormone (1–34) on Markers of Bone Turnover and Bone Density in Postmenopausal Women: The PrOP Study

J. Cauley, S. Sereika, A. F. Stewart, 2014 .